Biocon's IPO was oversubscribed 33 times
Biocon becomes the first company worldwide to develop
In 1989, Biocon became the first Indian biotech company
Australia has conferred the‘Order of Australia' honour to-
Kiran Mazumdar-Shaw(Biocon founder).
Biocon, today is a billion-dollar company
and Asia's largest Bio Parma concern.
Biocon's market cap on the SENSEX is 34
thousand 644 crores(as on 28 January).
In 2006, Kiran Mazumdar-Shaw, who founded Biocon, one of India's first biotech companies,
was rated India's richest woman.
Biocon Limited on 24 December 2015 launched
the generic versionof hepatitis C drug in the Indian market.
Biocon's Chairman and Managing Director,
Kiran Mazumdar Shaw is the first woman leader to reach 1 billion dollar networth.
Mazumdar-Shaw, ranked 65 on the list, is India's richest self-made woman and
founder of the country's largest biopharmaceutical firm Biocon.
The pharmaceutical product Insulin glargine manufactured by Biocon Limited(India) was registered with the State Register
of Medicinal Products of Ukraine in 2017.
The Moldovan journalists suppose that the Indian company Biocon Limited might even be unaware of the fact that
their product has caused the multi- million insulin scandal in Moldova far away.
As early as 1984,
she began to develop a research and development team at Biocon, focusing on discovery of novel enzymes
and on development of novel techniques for solid substrate fermentation technology.
Biocon's IPO was oversubscribed 33 times
and its first day at the bourses closed with a market value of $1.11 billion, making Biocon only the second Indian company to cross the $1-billion mark on the first day of listing.